Login to Your Account



Cancer Drugs Likely Losers In Reformed Medicare Rules

By Randall Osborne


Monday, November 1, 2004

As ever, cancer drugs were much in the news last week, with Onyx Pharmaceuticals Inc.'s stock taking a 33 percent hit after the firm disclosed a likely delay in getting its renal cancer drug approved - and the drugs are going to make headlines even more often in the months ahead. The stories may be even sadder for approved drugs.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription